| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Former Director
6 companies
Schmid John P. is a Director at ANAB, with reported holdings spanning 6 companies. Recent filings cover 8 purchases and 3 sales. Those positions are worth an estimated $4.9M at current prices.
Our model assigns Schmid John P. a strong insider score of 80/100, based on 8 past trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +75.9%.
Schmid John P.'s largest disclosed position is in ANAB as Director, worth about $2.2M. The recent filings there lean toward selling, a net 20,645 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | BLSM Blossomhill Therapeutics, Inc. Common Stock | Director | Buy | 6,000 | $16.00 | $96,000.00 | New | - | - | |
| Mar 30, 2026 | ANAB Anaptysbio, Inc. | Director | Sell | 20,645 | $56.11 | $1,158,451.42 | -16.6% | +71.0% | - | |
| Aug 12, 2024 | XERS Xeris Biopharma Holdings, Inc. | Director | Buy | 4,515 | $2.25 | $10,147.01 | +21.8% | +45.8% | +224.4% | |
| Aug 9, 2024 | XERS Xeris Biopharma Holdings, Inc. | Director | Buy | 4,285 | $2.37 | $10,134.03 | +26.1% | +44.8% | +194.8% | |
| May 10, 2024 | XERS Xeris Biopharma Holdings, Inc. | Director | Buy | 5,400 | $1.91 | $10,314.00 | +49.1% | +26.7% | +184.7% | |
| Mar 25, 2024 | DSGN Design Therapeutics, Inc. | Director | Buy | 26,965 | $3.70 | $99,738.48 | +294.5% | -10.2% | +22.7% | |
| Mar 14, 2024 | XERS Xeris Biopharma Holdings, Inc. | Director | Buy | 4,500 | $2.16 | $9,720.00 | +69.2% | +5.2% | +126.3% | |
| Nov 16, 2023 | XERS Xeris Biopharma Holdings, Inc. | Director | Buy | 6,500 | $1.51 | $9,815.00 | New | +104.5% | +86.0% |